glp-1 agonist common side effects GI Adverse of Glucagon-Like Peptide-1 Receptor Agonists GLP-1 Agonists For Obesity In

Research in earlier phases or small trials include evaluation of GLP-1s for cystic fibrosis-related diabetes, polycystic ovarian syndrome (PCOS), chronic obstructive pulmonary disease (COPD), Prader-Willi syndrome (PWS), asthma, substance or alcohol use disorder, and as add-on to insulin for type 1 diabetes (T1DM)

They can offer medical advice and create a plan that fits your health needs, goals, and access to care

Clinical trial data from the STEP 1 and SURMOUNT-1 trials show that patients typically achieve 1015% total body weight loss with semaglutide 2.4 mg weekly (Wegovy) and 1520% with tirzepatide 1015 mg weekly (Zepbound) over 1218 months

& Lavecchia, A

Microdosing of GLP-1's The Rationale for Microdosing While GLP-1 receptor agonists (GLP-1 RAs) are effective treatments, higher doses can cause gastrointestinal side effects such as nausea and vomiting